Optimizing Control in T2D: Part 2 in a Quality Improvement Program for Primary Care
May 29, 2018
May 29, 2019
Scroll to the Bottom of this Information to Begin this Course
This activity is provided by Horizon CME.
Supported by an educational grant from Sanofi US.
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)™
All other health care professionals completing this course will be issued a statement of participation.
This activity has been designed to meet the educational needs of primary care clinicians, nurse practitioners (NPs), physician assistants (PAs) and other health care professionals involved in the care of patients with diabetes.
Upon completion of this activity, participants should be able to:
- Outline the benefits, indications, and role of continuous glucose monitoring (CGM) in optimizing glycemic control in patients with T2DM
- Describe the clinical and pharmacokinetic/pharmacodynamic (PK/PD) differences between ultralong-acting and conventional basal insulins
- Incorporate newer basal insulins to optimize diabetes therapy and achieve A1C goals
Carol Wysham, MD
Clinical Professor of Medicine
University of Washington School of Medicine
Rockwood Center for Diabetes and Endocrinology
Davida F. Kruger, MSN, APN-BC, BC-ADM
Certified Nurse Practitioner
Henry Ford Health System, Division of Endocrinology
Diabetes and Bone Disease
Felice Caldarella, MD, FACE, FACP, CDE
Center for Endocrine Health
Hunterdon Medical Center
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the providership of Horizon CME. Horizon CME is accredited by the ACCME to provide continuing medical education for physicians.
Horizon CME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Learner Assurance Statement
Horizon CME requires instructors, planners, managers and other individuals who are in a position to influence the content of this activity to disclose any real or apparent conflict of interest (COI) which may arise as a result of prospective faculty members' relevant relationships with drug or device manufacturer(s). Horizon CME is committed to resolving all conflicts of interest and retaining only those speakers with financial interest conflicts that can be reconciled with the goals and educational integrity of the CME activity.
Carol Wysham, MD: Dr. Wysham has served on Speakers Bureaus for Astra Zeneca, Boehringer Ingelheim, Eli Lilly and Company, Janssen, Insulet, Novo Nordisk and Sanofi. She has served on Advisory Boards for Abbott, Astra Zeneca, Janssen, Novo Nordisk and Sanofi. She has provided services for non-CME promotional purposes for Sanofi and Novo Nordisk.
Davida F. Kruger, MSN, APN-BC, BC-ADM: Ms. Kruger has served on Advisory Boards for Abbott, Eli Lilly and Company, Janssen, Novo Nordisk, sanofi, Dexcom, Intarcia and Merck. She has served on Speakers Bureaus for Abbott, Astra Zeneca, Boehringer Ingelhemi/Lilly, Eli Lilly and Company, Janssen, Novo Nordisk, Dexcom, Insulet and Valeritas.
Her institution has received grants/research support from Abbott, Astra Zeneca, Eli Lilly and Company, Novo Nordisk, Dexcom, and Lexicon. Ms. Kruger is a stockholder in Dexcom.
Felice Caldarella, MD, FACE, FACP, CDE: Dr. Calderella discloses no relevant financial relationships with ACCME-defined commercial interests during the past 12 months.
Horizon Planner Disclosures
Horizon CME planners, non-faculty contributors and others involved in the planning, development, and editing/review of the content disclosed no relevant financial relationships with any ACCME-defined commercial interests during the past 12 months.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
How to Claim Credit
By reviewing the course content and successfully completing the post-test and evaluation, physicians are entitled to receive 1.0 AMA PRA Category 1 Credit(s)™. Statement of credit will be available to print from your user history page.
- Read the learning objectives and faculty disclosures.
- Participate in the activity.
- Complete the post-test and activity evaluation.
- Physicians who successfully complete the post-test and evaluation will receive CME credit. You must score with an 75% or higher on the post-test to receive credit for this activity.
- All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
COURSE VIEWING REQUIREMENTS
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.
For video playback, install the latest version of Flash or Quicktime.